Godman, B., Hill, A., Simoens, S., Selke, G., Selke Krulichová, I., Zampirolli Dias, C., Martin, A. P., Oortwijn, W., Timoney, A., Gustafsson, L. L., Voncina, L., Kwon, H., Gulbinovic, J., Gotham, D., Wale, J., Cristina Da Silva, W., Bochenek, T., Allocati, E., Kurdi, A., Ogunleye, O. O., Meyer, J. C., Hoxha, I., Malaj, A., Hierländer, C., Sauermann, R., Hamelinck, W., Petrova, G., Laius, O., Langner, I., Yfantopoulos, J., Joppi, R., Jakupi, A., Greiciute-Kuprijanov, I., Vella Bonanno, P., Piepenbrink, J. (., de Valk, V., Wladysiuk, M., Marković-Peković, V., Mardare, I., Fürst, J., Tomek, D., Obach Cortadellas, M., Zara, C., Pontes, C., McTaggart, S., Laba, T., Melien, Ø., Wong-Rieger, D., Bae, S., & Hill, R. (2021). potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert review of pharmacoeconomics & outcomes research, 21, 527–540. http://access.bl.uk/ark:/81055/vdc_100139925109.0x000017